Dr. Martens’ (DOCS) “Buy” Rating Reiterated at Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating restated by equities research analysts at Berenberg Bank in a research report issued on Friday, London Stock Exchange reports. They presently have a GBX 110 price target on the stock. Berenberg Bank’s target price indicates a potential upside of 58.05% from the stock’s current price.

Dr. Martens Stock Performance

Shares of Dr. Martens stock opened at GBX 69.60 on Friday. The stock has a market cap of £666.19 million, a price-to-earnings ratio of 29.00, a P/E/G ratio of 6.40 and a beta of 0.26. Dr. Martens has a twelve month low of GBX 59.15 and a twelve month high of GBX 97.05. The company’s fifty day moving average is GBX 74.43 and its 200 day moving average is GBX 70.86. The company has a quick ratio of 1.13, a current ratio of 2.61 and a debt-to-equity ratio of 108.85.

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.